Skip to main content
SpringerLink
Log in

Measles, Mumps and Rubella Vaccine, Autism and Inflammatory Bowel Disease

Advising Concerned Parents

  • Current Opinion
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Measles, mumps and rubella (MMR) vaccine has been used for almost 30 years in the US, 20 years in Sweden and Finland, and over 10 years in most of the rest of Europe. During this time, it has brought about a dramatic reduction in the morbidity and mortality due to measles and mumps, as well as a considerable reduction in the number of babies with the congenital rubella syndrome.

In spite of extensive evidence confirming the efficacy and safety of the vaccine, concerns have recently been raised about a possible link with autism and bowel problems. These arose principally from a research group in the UK, but have now spread to other countries. In the UK this has caused a fall in the uptake of the vaccine with fears of possible outbreaks of measles and mumps in some groups of children. Over the last 3 years a number of studies have addressed this possible link between MMR and autism and inflammatory bowel disease. Studies from the US, UK, Sweden, and Finland have all failed to demonstrate a link. Amongst others, the American Academy of Pediatrics, the Royal College of Paediatrics and Child Health, the Institute of Medicine, and the World Health Organization have all considered the evidence and endorsed the continuing use of the vaccine. No regulatory body in the world has changed its policy as a result of this hypothesized link.

Professionals and parents can be assured that MMR is well tried and tested and one of the most successful interventions in healthcare.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Data on file, Office for National Statistics, 2002

  2. Data on file, Communicable Disease Surveillance Centres, 2002

  3. Groseclose SL, Hall PA, Knowles CM, et al., on behalf of CDC. Summary of notifiable diseases, United States, 1999. MMWR Morb Mortal Wkly Rep 2001; 48(53): 1–104

    Google Scholar 

  4. Bottiger M, Christenson B, Taranger J, et al. Mass vaccination programme aimed at eradicating measles, mumps and rubella in Sweden: vaccination of school children. Vaccine 1983; 3: 113–6

    Article  Google Scholar 

  5. Plotkin S, Wharton M. Mumps vaccine. In: Plotkin S, Orenstein W, editors. Vaccines. Philadelphia (PA): WB Saunders Company, 1999: 267–92

    Google Scholar 

  6. King GE, Markowitz LE, Patricia PA, et al. Clinical efficacy of measles vaccine during the 1990 measles epidemic. Pediatr Infect Dis J 1991; 10: 883–7

    Article  PubMed  CAS  Google Scholar 

  7. Department of Vaccines and Biologicals. WHO vaccine preventable diseases: monitoring system. 2000 global summary. Geneva: World Health Organization, 2000

    Google Scholar 

  8. Peltola H, Heinonen OP, Valle M, et al. The elimination of indigenous measles, mumps and rubella from Finland by a 12-year, two dose vaccination program. N Engl J Med 1994; 331: 1397–402

    Article  PubMed  CAS  Google Scholar 

  9. Wakefield AJ, Montgomery SM. Measles mumps rubella vaccine: through a glass darkly. Adverse Drug React Toxicol Rev 2000; 19: 265–83

    PubMed  CAS  Google Scholar 

  10. Combined measles, mumps and rubella vaccines: response of the Medicines Control Agency and Department of Health to issues raised in papers published in Adverse Drug Reactions and Toxicological Reviews, Vol. 19, No. 4, 2000. London: Department of Health, 2001

  11. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine: a double-blind placebo-controlled trial in twins. Lancet 1986; I: 939–42

    Article  Google Scholar 

  12. Ekbom A, Wakefield AJ, Zack M, et al. Perinatal measles infection and subsequent Crohn’s disease. Lancet 1994; 344: 508–10

    Article  PubMed  CAS  Google Scholar 

  13. Thompson NP, Montgomery SM, Pounder RE, et al. Is measles vaccination a risk factor for inflammatory bowel disease. Lancet 1995; 345: 1071–4

    Article  PubMed  CAS  Google Scholar 

  14. Nielsen LL, Nielsen NM, Melbye M, et al. Exposure to measles in utero and Crohn’s disease: Danish register study. BMJ 1998; 316(7126): 196–7

    Article  PubMed  CAS  Google Scholar 

  15. Feeney MCA, Winwood P, Snook J, for the East Dorset Gastroenterology Group. A case-control study of measles vaccination and inflammatory bowel disease. Lancet 1997; 350: 764–6

    Article  PubMed  CAS  Google Scholar 

  16. Chadwick N, Bruce IJ, Schepelmann S, et al. Measles virus DNA is not identified in inflammatory bowel disease using hybrid capture and reverse transcriptase followed by polymerase chain reaction. J Med Virol 1998; 55: 305–11

    Article  PubMed  CAS  Google Scholar 

  17. Davis RL, Kramarz P, Bohlke K, et al. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease. Arch Pediatr Adolesc Med 2001; 155: 354–9

    PubMed  CAS  Google Scholar 

  18. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998; 351: 1327–8

    Article  Google Scholar 

  19. Chen RT, DeStefano F. Vaccine adverse events: causal or coincidental. Lancet 1998; 351: 611–2

    Article  PubMed  CAS  Google Scholar 

  20. Gilberg C, Heijbel H. MMR and autism. Autism 1998; 2: 423–4

    Article  Google Scholar 

  21. Taylor B, Miller E, Farrington CP, et al. Autism and measles, mumps and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999; 353: 2026–9

    Article  PubMed  CAS  Google Scholar 

  22. Spitzer WO. A sixty day war of words: is MMR linked to autism [letter]. Adverse Drug React Toxicol Rev 2001; 20: 47–55

    PubMed  CAS  Google Scholar 

  23. Farrington CP, Miller E, Taylor B. MMR and autism: further evidence against a causal association. Vaccine 2001; 19: 3632–5

    Article  PubMed  CAS  Google Scholar 

  24. Fombonne E, Chakrabarti S. No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics 2001; 108(4): E58

    Article  PubMed  CAS  Google Scholar 

  25. Taylor B, Miller E, Lingam R, et al. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ 2002; 324: 393–6

    Article  PubMed  Google Scholar 

  26. Halsey N, Hyman SL, and the Conference Writing Panel. Measles-mumps-rubella vaccine and the autistic spectrum disorder: report from the New Challenges in Childhood Immunizations Conference convened in Oak Brook, Illinois, June 12–13 2000. Pediatrics 2001; 107: E84

    Article  PubMed  CAS  Google Scholar 

  27. Stratton K, Gable A, Shetty P, et al., editors. Immunization safety review: measles-mumps-rubella vaccine and autism. The Immunization Safety Review Committee, Institute of Medicine. Washington, DC: National Academy Press, 2001

    Google Scholar 

  28. Ghosh S, Armitage E, Wilson D, et al. Detection of persistent measles virus infection in Crohn’s disease: current status of experimental work. Gut 2001; 48: 748–52

    Article  PubMed  CAS  Google Scholar 

  29. Wakefield AJ. Testimony before Congressional Oversight Committee on Autism and Immunisation, April 6 2000 [online]. Available from URL: http://www.gpo.gov/congress/house [Accessed 2002 Jul 23]

  30. Miller E, Goldacre M, Pugh S, et al. Risk of aseptic meningitis after measles, mumps and rubella vaccine in UK children. Lancet 1993; 341: 979–82

    Article  PubMed  CAS  Google Scholar 

  31. Davidkin I, Peltola H, Leinikki PMV. Duration of immunity induced by two-dose measles, mumps and rubella (MMR) vaccination: a 15-year follow-up in Finland. Vaccine 2000; 18: 3106–12

    Article  PubMed  CAS  Google Scholar 

  32. Ramsay M, Gay N, Miller E, et al. The epidemiology of measles in England and Wales: rationale for the 1994 national vaccination campaign. Commun Dis Rep CDR Rev 1994; 4: R141–6

    PubMed  CAS  Google Scholar 

  33. Schlegel M, Osterwalder JJ, Galeazzi RL, et al. Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study [published erratum appears in BMJ 1999; 319 (7208): 477]. BMJ 1999; 319: 352

    Article  PubMed  CAS  Google Scholar 

  34. Uhlmann V, Martin CM, Sheils O, et al. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. Mol Pathol 2002; 55: 84–90

    Article  PubMed  CAS  Google Scholar 

  35. Morris A, Aldulaimi D. New evidence for a viral pathogenic mechanism for new variant inflammatory bowel disease and development disorder [comment]. Mol Pathol 2002; 55: 83

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Both authors have received funding from vaccine manufacturers, as well as other sources, to attend educational meetings and conduct research. They receive no personal income from such sources.

Author information

Authors and Affiliations

  1. Department of Child Health, St George’s Hospital, Tooting, London, SW17 OQT, England

    David A. C. Elliman

  2. Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, London, England

    Helen E. Bedford

Authors
  1. David A. C. Elliman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helen E. Bedford
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David A. C. Elliman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Elliman, D.A.C., Bedford, H.E. Measles, Mumps and Rubella Vaccine, Autism and Inflammatory Bowel Disease. Pediatr-Drugs 4, 631–635 (2002). https://doi.org/10.2165/00128072-200204100-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128072-200204100-00001

Keywords

Search

Navigation